Marker Therapeutics, Inc. MRKR · Stock Open Marker Therapeutics, Inc. in new tab
Marker Therapeutics, Inc. Analysis (MRKR)
Is Marker Therapeutics, Inc. a good investment? Marker Therapeutics, Inc. (MRKR) is currently trading at 1.21 USD. Market analysts have a consensus price target of 7.87 USD. This suggests a potential upside from current levels.
Earnings Schedule: Marker Therapeutics, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.53.
Investor FAQ
Does Marker Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Marker Therapeutics, Inc.?
Marker Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.38.
Company Profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
| Split Date | Split Ratio to 1 |
|---|---|
| June 28, 2007 | 0.4 |
| July 27, 2009 | 1:10 |
| Feb. 25, 2014 | 1:100 |
| Sept. 16, 2016 | 0.08 |
| Jan. 27, 2023 | 1:10 |
Community Discussion